Wednesday , 16 January 2019
Breaking News

Tag Archives: aurobindo

Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months

Aurobindo Pharma is expecting to receive an approval for its first biosimilar product in the US in the next 12-18 months, while in Europe, the company hopes a green signal by 2022. Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain ... Read More »

Aurobindo Pharma planning to launch oncology, respiratory products in US

Aurobindo Pharma is planning to launch first set of oncology, respiratory, complex injectables and topical products in the US in the next three years as part of plans to build a robust specialty products portfolio. The company is also planning to launch first set of biosimilars and vaccines in growth markets during the same period. Aurobindo Pharma is engaged in ... Read More »

Aurobindo Pharma reports 22% fall in Q2 consolidated net profit

Aurobindo Pharma has reported results for second quarter ended September 30, 2018. The company has reported a fall of 49.40% in its net profit at Rs 380.95 crore for the quarter under review as compared to Rs 752.83 crore for the same quarter in the previous year. However, total income of the company increased by 3.14% at Rs 3,170.39 crore ... Read More »

Aurobindo Pharma’s arm enters into agreement with Advent Pharma

Aurobindo Pharma’s wholly owned subsidiary — Aurobindo Pharma USA Inc. — has entered into an agreement to acquire a product under development and related assets from Advent Pharmaceuticals Pty, Australia, through AuroScience Pty, Melbourne, a 100% subsidiary of Aurobindo Pharma USA Inc. This acquisition will provide an opportunity to acquire assets that would be used for specialty generics business and ... Read More »

Aurobindo Pharma receives USFDA’s nod for Azithromycin Oral Suspension

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Azithromycin Oral Suspension 100 mg /5 mL and 200 mg/5 mL. Azithromycin oral suspension, a generic version of Pfizer Inc’s Zithromax oral suspension. The product will be launched in November 2018. Azithromycin oral suspension is indicated for the treatment of patients with ... Read More »